EE479 Cost-Effectiveness of Olaparib Compared to Rucaparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer (MCRPC) in United States
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.727
https://www.valueinhealthjournal.com/article/S1098-3015(22)00928-7/fulltext
Title :
EE479 Cost-Effectiveness of Olaparib Compared to Rucaparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer (MCRPC) in United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00928-7&doi=10.1016/j.jval.2022.04.727
First page :
Section Title :
Open access? :
No
Section Order :
10654